Could SNG001 be the 007 of the coronavirus? The British laboratory Synairgen has just unveiled the first results of its clinical trials on this drug, which would be able to reduce the risk of developing a severe form of Covid-19 by 79%, underlines a AFP dispatch taken over by the Parisian.
The treatment works on the most famous symptom of Covid-19: respiratory problems. He is inhaled by patients, and is intended to strengthen the immune response of the lungs. It works as a kind of shield against the virus, at the heart of the respiratory system. It would, according to British researchers at the University of Southampton, prevent infected patients from lacking oxygen to the point of being put on a ventilator.
Accelerated recovery
Another figure taken from the study: the chances of recovering during the period of treatment with SNG001 are doubled. The drug therefore also allowsaccelerate the recovery phenomenon. In the study conducted in the United Kingdom, on 101 patients dispatched to 9 hospitals (between March 30 and May 27), doctors found three deaths in patients who had received a placebo, but none in patients placed on SNG001.
This drug, which could greatly improve the care of patients in hospital, has so far only been tested on too small a sample of patients. It will first have to be studied on a larger scale before being validated as a treatment against Covid-19.
Read also:
- Covid-19: what do we know about the after-effects?
- Coronavirus vaccine (Covid-19): 2 vaccine candidates produce an immune response
- Immunity and Covid-19: it could disappear in a few months
